RA Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

RA Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,115,008	Closed	-$61.3M	–	103
2021 Q4	$61.3M	Hold	3,115,008	–	–	1.08%	27
2021 Q3	$100M	Hold	3,115,008	–	–	1.39%	23
2021 Q2	$105M	Hold	3,115,008	–	–	1.69%	16
2021 Q1	$117M	Sell	3,115,008 -710,000	-19%	-$29.7M	1.76%	14
2020 Q4	$127M	Hold	3,825,008	–	–	1.78%	13
2020 Q3	$140M	Hold	3,825,008	–	–	2.57%	8
2020 Q2	$126M	Buy	3,825,008 +117,600	+3%	+$4.52M	2.45%	12
2020 Q1	$95.7M	Buy	3,707,408 +60,600	+2%	+$2.03M	3.02%	11
2019 Q4	$114M	Buy	+3,646,808	New	+$91.7M	3.44%	9

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

RA Capital Management's PHAT Position: Q1 2022 in Review

RA Capital Management sold out of Phathom Pharmaceuticals (PHAT) in Q1 2022, closing a stake of 3,115,008 shares — an estimated $61.3M sold.

RA Capital Management first reported a position in PHAT in Q4 2019 and held it in 9 quarters. The position peaked at $140M in Q3 2020. 83 funds tracked by Wall St. Rank hold PHAT as of Q1 2022.

RA Capital Management reported no remaining Phathom Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
RA Capital Management sold 3,115,008 Phathom Pharmaceuticals shares in Q1 2022, an estimated $61.3M.
RA Capital Management first reported a position in Phathom Pharmaceuticals in Q4 2019 and held it in 9 quarters.
RA Capital Management's Phathom Pharmaceuticals position peaked at $140M in Q3 2020.
83 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2022.

Based on RA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.